Percentage of REVEAL registry patients on a prostacyclin-class therapy (N=2438)1
FC III | FC IV |
---|---|
46% | 59% |
Note: Not all patients were appropriate candidates for prostacyclin-class therapy.
FC=functional class; REVEAL=Registry to Evaluate Early And Long-term PAH disease management.
Remodulin® (treprostinil) Injection
Indication
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

Reference: 1. Badesch DB, Raskob GE, Elliott G, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137(2):376-387.